肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌

2019-02-18 不详 MedSci原创

布加替尼非小细胞肺癌酪氨酸激酶抑制剂
关注

英国国家健康与护理研究所（NICE）推荐使用Alunbrig（布加替尼）治疗Xalkori（克唑替尼）作用后ALK阳性的晚期非小细胞肺癌NSCLC患者。

英国国家健康与护理研究所（NICE）推荐使用Alunbrig（布加替尼）治疗Xalkori（克唑替尼）作用后ALK阳性的晚期非小细胞肺癌NSCLC患者。

NICE表示Xalkori不再被认为是ALK阳性NSCLC患者的一线治疗药物。

目前，ceritinib（塞瑞替尼）是该类肺癌患者的二线治疗药物。根据ASCEND-5试验结果，服用ceritinib的患者平均存活率为18个月。ALTA临床试验的结果却显示，服用Alunbrig的Xalkori-进展型NSCLC患者的平均存活率达34个月。

最终评估文件（FAD）称，Alunbrig的毒性也低于Zykadia。

Alunbrig是需要口服的、酪氨酸激酶抑制剂，28x180mg片剂的建议定价为4900英镑，但根据其商业协议，制造商Takeda将为NHS提供保密的折扣。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1986780, encodeId=2a3c1986e8045, content=<a href='/topic/show?id=7e444839ec7' target=_blank style='color:#2F92EE;'>#布加替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48397, encryptionId=7e444839ec7, topicName=布加替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Oct 07 08:45:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678107, encodeId=c2e816e8107c9, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2381, encryptionId=efb323810d, topicName=Alunbrig)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 28 20:45:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059788, encodeId=5cfc2059e8824, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Nov 08 10:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289039, encodeId=bf981289039f2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 06:45:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-10-07 陈吴1234

    #布加替尼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1986780, encodeId=2a3c1986e8045, content=<a href='/topic/show?id=7e444839ec7' target=_blank style='color:#2F92EE;'>#布加替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48397, encryptionId=7e444839ec7, topicName=布加替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Oct 07 08:45:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678107, encodeId=c2e816e8107c9, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2381, encryptionId=efb323810d, topicName=Alunbrig)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 28 20:45:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059788, encodeId=5cfc2059e8824, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Nov 08 10:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289039, encodeId=bf981289039f2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 06:45:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-09-28 仁者大医

    #Alunbrig#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1986780, encodeId=2a3c1986e8045, content=<a href='/topic/show?id=7e444839ec7' target=_blank style='color:#2F92EE;'>#布加替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48397, encryptionId=7e444839ec7, topicName=布加替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Oct 07 08:45:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678107, encodeId=c2e816e8107c9, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2381, encryptionId=efb323810d, topicName=Alunbrig)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 28 20:45:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059788, encodeId=5cfc2059e8824, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Nov 08 10:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289039, encodeId=bf981289039f2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 06:45:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-11-08 lingaifan

    #非小细胞#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1986780, encodeId=2a3c1986e8045, content=<a href='/topic/show?id=7e444839ec7' target=_blank style='color:#2F92EE;'>#布加替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48397, encryptionId=7e444839ec7, topicName=布加替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Oct 07 08:45:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678107, encodeId=c2e816e8107c9, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2381, encryptionId=efb323810d, topicName=Alunbrig)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 28 20:45:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059788, encodeId=5cfc2059e8824, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Nov 08 10:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289039, encodeId=bf981289039f2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 06:45:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-20 fusion

    #NICE#

    0